JP6019015B2 - ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法 - Google Patents

６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法 Download PDF

Info

Publication number
JP6019015B2
JP6019015B2 JP2013513289A JP2013513289A JP6019015B2 JP 6019015 B2 JP6019015 B2 JP 6019015B2 JP 2013513289 A JP2013513289 A JP 2013513289A JP 2013513289 A JP2013513289 A JP 2013513289A JP 6019015 B2 JP6019015 B2 JP 6019015B2
Authority
JP
Japan
Prior art keywords
resistant
leukemia
pharmaceutical composition
drug
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013513289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528620A5 (https=
JP2013528620A (ja
Inventor
メルクウリオ フランク
メルクウリオ フランク
ダブリュー．エイチ． チャン クイルエ
ダブリュー．エイチ． チャン クイルエ
Original Assignee
ビオトヘルイク， インコーポレイテッド
ビオトヘルイク， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオトヘルイク， インコーポレイテッド, ビオトヘルイク， インコーポレイテッド filed Critical ビオトヘルイク， インコーポレイテッド
Publication of JP2013528620A publication Critical patent/JP2013528620A/ja
Publication of JP2013528620A5 publication Critical patent/JP2013528620A5/ja
Application granted granted Critical
Publication of JP6019015B2 publication Critical patent/JP6019015B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013513289A 2010-06-01 2011-06-01 ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法 Expired - Fee Related JP6019015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35043810P 2010-06-01 2010-06-01
US61/350,438 2010-06-01
PCT/US2011/038702 WO2011153199A1 (en) 2010-06-01 2011-06-01 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone

Publications (3)

Publication Number Publication Date
JP2013528620A JP2013528620A (ja) 2013-07-11
JP2013528620A5 JP2013528620A5 (https=) 2014-07-17
JP6019015B2 true JP6019015B2 (ja) 2016-11-02

Family

ID=44534598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513289A Expired - Fee Related JP6019015B2 (ja) 2010-06-01 2011-06-01 ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法

Country Status (8)

Country Link
US (2) US20130178503A1 (https=)
EP (1) EP2585063A1 (https=)
JP (1) JP6019015B2 (https=)
CN (1) CN103153309A (https=)
AU (1) AU2011261501B2 (https=)
CA (1) CA2801003A1 (https=)
MX (1) MX342465B (https=)
WO (1) WO2011153199A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2576513A1 (en) 2010-06-01 2013-04-10 Biotheryx Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
CN116077522B (zh) * 2023-03-09 2024-01-26 青岛市中心医院 一种用于治疗白血病的治疗制剂

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3972888A (en) 1972-03-25 1976-08-03 Hoechst Aktiengesellschaft Process for the preparation of 1-hydroxy-pyridones
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992005190A1 (en) * 1990-09-17 1992-04-02 The Children's Medical Center Corporation Deoxyhypusyl hydroxylase inhibitors
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
JP3170176B2 (ja) * 1995-05-17 2001-05-28 大塚製薬株式会社 薬剤耐性獲得癌細胞の検出方法
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
JP2000508339A (ja) 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
JP2006519752A (ja) * 2002-05-31 2006-08-31 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 慢性骨髄性白血病を治療するために有用な医薬組成物
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
CA2547196A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20080014192A1 (en) * 2006-05-23 2008-01-17 Poeta Maurizio D Methods For The Diagnosis And Treatment of Fungal Infections Caused By Microorganisms Producing Glucosylceramide
CN102239178B (zh) * 2008-10-02 2017-06-23 Vib研究所 抑制PlGF以治疗费城染色体阳性白血病
US20110212176A1 (en) * 2008-10-31 2011-09-01 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders

Also Published As

Publication number Publication date
WO2011153199A1 (en) 2011-12-08
US20130178503A1 (en) 2013-07-11
CA2801003A1 (en) 2011-12-08
MX342465B (es) 2016-09-30
US20150342942A1 (en) 2015-12-03
CN103153309A (zh) 2013-06-12
AU2011261501A1 (en) 2013-01-10
AU2011261501B2 (en) 2016-01-21
EP2585063A1 (en) 2013-05-01
JP2013528620A (ja) 2013-07-11
MX2012013878A (es) 2013-06-28

Similar Documents

Publication Publication Date Title
JP2024107167A (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP5645667B2 (ja) 増殖性疾患を治療するための、Ｎ−（５−ｔｅｒｔ−ブチル−イソキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，ｌ−ｂ］［ｌ，３］ベンゾチアゾール−２−イル］フェニル｝尿素の投与方法
JP2025116875A (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
RU2543348C2 (ru) Способ лечения путем применения комбинированной терапии
JP5844354B2 (ja) ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
BR112020006039A2 (pt) formulações de niraparibe
JP7222042B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
BR112021013675A2 (pt) Formulações de comprimido de liberação modificada que contêm inibidores de fosfodiesterase
US20210196730A1 (en) Compound and use thereof
JP2019529491A (ja) 毛髪の成長を刺激するためのアルファ−ケトブチレート、アルファ−ケトグルタレート、および２−ヒドロキシブチレート
TW202045185A (zh) 用於治療過度增生疾病之atr激酶抑制劑
JP6019015B2 (ja) ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
JP7756097B2 (ja) 治療剤ナノ粒子および調製方法
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
CN117561254A (zh) 用于肺癌治疗的嘧啶基氨基苯
JP2011520934A (ja) 筋ジストロフィー治療用化合物
CN119215165B (zh) Plk1抑制剂在制备治疗卵巢高钙血症型小细胞癌的药物中的应用
JP2025507901A (ja) Ｐｉ３ｋ阻害剤とｐｄ－１阻害剤との併用療法
HK40099904A (en) Modified release tablet formulations containing phosphodiesterase inhibitors
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161003

R150 Certificate of patent or registration of utility model

Ref document number: 6019015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees